Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Fei Wen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Isocitrate Dehydrogenase, Glioma, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Qinglan Project of Jiangsu Province of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
The targeting of cancer cell intrinsic metabolism has emerged as a promising strategy for antitumor intervention. In the study, we identified the first-in-class small molecules that effectively inhibit both mutant isocitrate dehydrogenase 1 (mIDH1) and nicotinamide phosphoribosyltransferase (NAMPT), two crucial targets in cancer metabolism, through structure-based drug design. Notably, compound 23h exhibits excellent and balanced inhibitory activities against both mIDH1 (IC50 = 14.93 nM) and NAMPT (IC50 = 12.56 nM), leading to significant suppression of IDH1-mutated glioma cell (U87 MG-IDH1R132H) proliferation. Significantly, compound 23h has the ability to cross the blood-brain barrier (B/P ratio, 0.76) and demonstrates remarkable in vivo antitumor efficacy (20 mg/kg) in the U87 MG-IDH1R132H orthotopic transplantation mouse models without any notable toxicity. This proof-of-concept investigation substantiates the viability of discovering small molecules that concurrently target mIDH1 and NAMPT, providing valuable leads for the treatment of glioma and an efficient approach for the discovery of multitarget antitumor drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, China.
ORCID-Profile: Xiaoming Zha
Förderung
- Qinglan Project of Jiangsu Province of China
- National Natural Science Foundation of China
Zitieren
APA
Wen, F., Gui, G., Wang, X., Qin, A., Ma, T., Chen, H., Li, C., & Zha, X. (2024). Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02482
Vancouver
Wen F, Gui G, Wang X, Qin A, Ma T, Chen H, et al. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02482
BibTeX
@article{Wen2024,
author = {Wen, Fei and Gui, Gang and Wang, Xiaoyu and Qin, Anqi and Ma, Tianfang and Chen, Hui and Li, Chunzheng and Zha, Xiaoming},
title = {Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02482}
}
EUVIMED